profit from every ₹100 of sales.
₹0₹100
Indegene
₹665.45-0.06% today
+26.2% in 1 year
1-year low ₹424.301-year high ₹665.85
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹39.95 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Indegene sold, what it kept, and what it did with the cash.
Sales went from ₹23.1 billion in 2023 to ₹35.1 billion in 2026, with ₹4.01 billion of profit last year.
SalesProfit
Indegene handed back 8% of the cash it generated last year.
₹480M
Free cash flow 2026₹6.1B
Bought back its own shares–
Paid as dividends₹480M
Cash vs. debt₹3.0B vs. ₹1.4B
Indegene vs. similar companies
Indegene grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Indegene | 40.0× · Expensive | ||
 Veeva Systems | 53.7× · Expensive | ||
 Pro Medicus | 183.7× · Very expensive | ||
 Hinge Health | No profit yet | ||
 M3 | 30.1× · Expensive |
AI analysis
An AI analyst reads Indegene's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 23,061 | 25,896 | 28,393 | 35,105 | |
| – | – | – | – | |
| 3,363 | 4,348 | 4,541 | 4,926 | |
| 4,541 | 5,810 | 6,415 | 6,708 | |
| 2,661 | 3,367 | 4,067 | 4,011 | |
| 11.12 | 14.09 | 17.02 | 16.62 | |
| – | – | – | – | |
| 14.6% | 16.8% | 16.0% | 14.0% | |
| 11.5% | 13.0% | 14.3% | 11.4% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 22,039 | 25,456 | 33,259 | 46,203 |
| Cash | 736 | 1,886 | 2,410 | 3,008 |
| Total debt | 5,026 | 4,896 | 1,016 | 1,444 |
| Total liabilities | 11,401 | 11,165 | 7,103 | 14,816 |
| 10,637 | 14,291 | 26,156 | 31,387 | |
| 239 | 239 | 239 | 241 | |
| 19.9% | 20.8% | 16.3% | 13.1% | |
| 25.0% | 23.6% | 15.5% | 12.8% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,302 | 5,077 | 4,419 | 6,508 | |
| 188 | 107 | 300 | 444 | |
| 1,114 | 4,970 | 4,119 | 6,064 | |
| Dividends paid | – | – | – | 480 |
| 0 | – | – | – | |
| 158 | 213 | 174 | 256 |
Valuation
- 40.0×
- –
- 2.79
- 3.9×
- 4.6×
- 26.4×
- 23.7×
- 3.8%
- 2.5%
- 0.3%
Profitability
- –
- 14.0%
- 11.4%
- –
- 12.4%
- 16.6%
- –
- –
- –
- –
Growth
- +15.0%
- +14.3%
- –
- –
- +0.3%
Financial health
- -0.2×
- 0.05
- –
- 28.2×
- 2.41
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 21%of 963
Top 40%of 894
Bottom 31%of 632
Top 36%of 908
Top 31%of 991
0.3%of the share price, paid each year
On $1,000 invested$3a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
12.0% of its profit
Room to growStretchedMore than it earns: 7.9%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
67Pass
Benjamin Graham
44No pass
Philip Fisher
59No pass
Peter Lynch
45No pass
Joel Greenblatt
13No pass
Charlie Munger
57No pass
Terry Smith
56No pass
Questions about Indegene
Is Indegene a good stock to buy?
A solid business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Indegene AI analysis
What does Indegene do?
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. It is in Health Information Services, based in Bengaluru, India.
Does Indegene pay a dividend?
Yes. At today's price the dividend is 0.3% a year, about 12% of its yearly profit. In 2026 it paid out ₹480 million in dividends.
Is Indegene stock halal?
Yes. Indegene passes our halal screen: its business is permitted and its debt is 0.9% of its market value, under the 30% limit. How we check
How has Indegene stock done over the past year?
Up 26.2% over the past twelve months, to ₹665.45. It traded between ₹424.30 and ₹665.85, close to its high.
Who are Indegene's competitors?
The largest listed companies in the same industry are Veeva Systems, Pro Medicus, Hinge Health and M3. The peers table on this page compares their profit, growth and price with Indegene's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.